David A. Lovejoy
Geen lopende functies
Vermogen: - $ op 30-04-2024
Profiel
David A.
Lovejoy was the founder of Protagenic Therapeutics, Inc. which was founded in 1994, where he held the title of Chief Scientific Officer.
He also held the position of Principal at the University of Toronto.
Dr. Lovejoy earned a doctorate degree from the University of Victoria.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 26-03-2023 | 0 ( -.--% ) | - $ | 30-04-2024 |
Eerdere bekende functies van David A. Lovejoy
| Bedrijven | Functie | Einde |
|---|---|---|
| University of Toronto | Corporate Officer/Principal | - |
| PROTAGENIC THERAPEUTICS, INC. | Oprichter | - |
Protagenic Therapeutics, Inc. /Old/
 Protagenic Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Protagenic Therapeutics, Inc. discovers and develops neuropeptides for the treatment of anxiety and depression based mood disorders. It focuses on the discovery and development of naturally occurring human brain hormones for the treatment of anxiety and depression based mood disorders. The firm products include PT00114 and PT00121, which are peptide-based formulations for the treatment of anxiety and depression disorders. The company is headquartered in New York, NY. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van David A. Lovejoy
| University of Victoria | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| PROTAGENIC THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Protagenic Therapeutics, Inc. /Old/
Protagenic Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Protagenic Therapeutics, Inc. discovers and develops neuropeptides for the treatment of anxiety and depression based mood disorders. It focuses on the discovery and development of naturally occurring human brain hormones for the treatment of anxiety and depression based mood disorders. The firm products include PT00114 and PT00121, which are peptide-based formulations for the treatment of anxiety and depression disorders. The company is headquartered in New York, NY. | Health Technology |
